|
Vaccine type | Phase | | Experimental design | PFS (mo) | OS (mo) | References |
|
Tumor lysate vaccine | I | 12 | Autologous DC loaded with tumor lysate | 15.5 | 23.4 | NCT00068510, [27] |
|
Tumor lysate vaccine | II | | Resiquimod, poly-ICLC | Ongoing | Ongoing | NCT01204684 |
|
DCVax-Brain | III | | 2/3 vaccine, 1/3 placebo with option of crossover at disease progression | Ongoing | Ongoing | NCT00045968 |
|
Tumor lysate vaccine | II | | Vaccine + standard therapy versus standard therapy alone | Ongoing | Ongoing | NCT01213407 |
|
Tumor lysate vaccine | II | 10 | DCs treated with PGE2 and TNF-, cervical lymph node injection | 9.5 | 28 | NCT00323115, [35] |
|
IMA950 multipeptide vaccine | I | | 11 tumor associated peptides (TUMAPs) + GM-CSF, cyclophosphamide, imiquimod | Ongoing | Ongoing | NCT01403285 |
|
Cancer stem cell vaccine, ICT-107 | I | 21 | Six synthetic peptides associated with CSCs loaded onto autologous DCs | 16.9 | 38.4 | [50] |
|
Cancer stem cell vaccine, ICT-107 | II | | Autologous DCs pulsed with immunogenic peptides from tumor antigens versus placebo | Ongoing | Ongoing | NCT01280552 |
|
Cancer stem cell vaccine | II | | Autologous DCs loaded with stem cell-like antigens from irradiated GBM versus placebo | Ongoing | Ongoing | NCT01567202 |
|
CMV vaccine (Pep-CMV) | I | | Intradermal Pep-CMV following chemoradiation | Ongoing | Ongoing | NCT01854099 |
|
Alpha type I DC peptide vaccine | I/II | 22 | Four peptides loaded onto alpha type I DCs + poly-ICLC, included GBM and anaplastic glioma | 4 in GBM 13 in anaplastic glioma | | NCT00766753, [61, 62] |
|
HSPPC-96 | I | 12 | Autologous tumor derived HSPPC-96 administered intradermally | | 47 weeks in immune responders 16 weeks in nonresponder | [67] |
|
HSPPC-96 | II | | Autologous tumor derived HSPPC-96 administered intradermally | Ongoing | Ongoing | NCT00905060, NCT00293423 |
|
HSPPC-96 | II | | Vaccine + bevacizumab versus bevacizumab alone | Ongoing | Ongoing | NCT01814813 |
|
Irradiated glioma cells with GM-K562 | I | | Admixture of lethally irradiate glioma cells with GM-CSF producing K562 injected intradermally | Ongoing | Ongoing | NCT00694330 |
|